ArticlePloS one2013
A novel mechanism of PPAR gamma induction via EGFR signalling constitutes rational for combination therapy in bladder cancer.
Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT03410667 (A Patient-centered Approach to Urinary Incontinence and Quality of Life in Children and Adolescents With Spina Bifida), which is not on this map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Patient-centered Approach to Urinary Incontinence and Quality of Life in Children and Adolescents With Spina Bifida
Who cites it
17 citing papers in PubMed, 35 citations in OpenAlex.
- CEBPB emerges as a key regulatory factor in human cancers through diverse molecular mechanisms and clinical implications.Discover oncology · 2025Review
- Viral and host network analysis of the human cytomegalovirus transcriptome in latency.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- ISG15 Is a Novel Regulator of Lipid Metabolism duringMicrobiology spectrum · 2022Article
- Vitamin D and Systems Biology.Nutrients · 2022Review
- LncRNA SNHG1 Facilitates Tumor Proliferation and Represses Apoptosis by Regulating PPARγ Ubiquitination in Bladder Cancer.Cancers · 2022Article
- Tackling of Renal Carcinogenesis in Wistar Rats byOxidative medicine and cellular longevity · 2021Article
- Antitumor Effects and the Compatibility Mechanisms of Herb PairFrontiers in pharmacology · 2020Article
- The role and function of PPARγ in bladder cancer.Journal of Cancer · 2020Review
- Article
- 5-HT induces PPAR γ reduction and proliferation of pulmonary artery smooth muscle cells via modulating GSK-3β/β-catenin pathway.Oncotarget · 2017Article
- Rosiglitazone induces apoptosis on human bladder cancer 5637 and T24 cell lines.International journal of clinical and experimental pathology · 2017Article
- Profiling of mRNA and long non-coding RNA of urothelial cancer in recipients after renal transplantation.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016Article
- Fatty acid activated PPARγ promotes tumorigenicity of prostate cancer cells by up regulating VEGF via PPAR responsive elements of the promoter.Oncotarget · 2016Article
- Targeted therapies in bladder cancer: an overview of in vivo research.Nature reviews. Urology · 2015Review
- Prognostic role of PPAR-γ and PTEN in the renal cell carcinoma.International journal of clinical and experimental pathology · 2015Article
- Intrinsic basal and luminal subtypes of muscle-invasive bladder cancer.Nature reviews. Urology · 2014Review
- Current Understanding on EGFR and Wnt/β-Catenin Signaling in Glioma and Their Possible Crosstalk.Genes & cancer · 2013Review
Corrections and comments
- Erratum issued
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTwo signalling molecules that are attractive for targeted therapy are the epidermal growth factor receptor (EGFR) and the peroxisome proliferator-activated receptor gamma (PPARγ). We investigated possible crosstalk between these 2 pathways, particularly in light of the recent evidence implicating PPARγ for anticancer therapy. PRINCIPAL
findingsAs evaluated by MTT assays, gefitinib (EGFR inhibitor) and DIM-C (PPARγ agonist) inhibited growth of 9 bladder cancer cell lines in a dose-dependent manner but with variable sensitivity. In addition, combination of gefitinib and DIM-C demonstrated maximal inhibition of cell proliferation compared to each drug alone. These findings were confirmed in vivo, where combination therapy maximally inhibited tumor growth in contrast to each treatment alone when compared to control (p<0.04). Induction of PPARγ expression along with nuclear accumulation was observed in response to increasing concentrations of gefitinib via activation of the transcription factor CCAT/enhancer-binding protein-β (CEBP-β). In these cell lines, DIM-C significantly sensitized bladder cancer cell lines that were resistant to EGFR inhibition in a schedule-specific manner.
conclusionThese results suggest that PPARγ agonist DIM-C can be an excellent alternative to bladder tumors resistant to EGFR inhibition and combination efficacy might be achieved in a schedule-specific manner.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.